Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Narhex Declares Bankruptcy; Involved in Xi’an JV

publication date: Feb 18, 2010
Narhex Life Sciences, an Australian pharma whose main asset was a China joint venture, has declared bankruptcy. In 2006, Narhex and China Shaanxi Dacheng International Trading Co. established a JV to develop a protease inhibitor for HIV. It also had licensed China rights to Cavidi diagnostic products, which could measure HIV viral load. From the start, the goal was to develop the products for use in China. The JV, which was called Xi’an Hex Life Sciences Co., was supported by the Xi’an High Tech Authority. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here